The purpose of this project is to evaluate a genetic risk score regarding the prognosis of the melanoma-specific survival (MSS), the relapse-free time (RFT), and the relapse-free survival (RFS) of patients with primary cutaneous melanoma. For example, the genetic risk score will be compared with the Sentinel Lymph Node (SLN) status as to the prognostic performance using recently developed statistical methods such as the Integrated Discrimination Improvement. All evaluations and comparisons will be carried out using datasets that were not used for developing the genetic risk score (external evaluation). Furthermore, the comparison modalities and methods will be pre-defined in study protocols, therefore providing fair and confirmatory results.

Beteiligte Wissenschaftlerin:
Dr. rer. nat. J. Köppe

Kooperationspartner:
Dr. rer. nat. Georg Brunner, NeraCare GmbH